Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cengild Medical BhdXKLS:0243 -2.56%61 Debt-to-EBITDA is 5.10 as of Mar. 2026, which is 225% above its 10-year median of 1.57. GuruFocus rates XKLS:0243 with a GF Score™ of 61/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Cengild Medical Bhd ranks worse than 71.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cengild Medical Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:0243'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.38 Med: 1.57 Max: 24.31
Current: 4.4
During the past 8 years, the highest Debt-to-EBITDA Ratio of Cengild Medical Bhd was 24.31. The lowest was 0.38. And the median was 1.57.
XKLS:0243's Debt-to-EBITDA is ranked worse than 71.13% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.21
vs XKLS:0243: 4.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cengild Medical Bhd Debt-to-EBITDA Related Terms
Cengild Medical Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cengild Medical Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0243 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Cengild Medical Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cengild Medical Bhd Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cengild Medical Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cengild Medical Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cengild Medical Bhd (XKLS:0243) has a Debt-to-EBITDA of 5.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cengild Medical Bhd. This is 225% above median its historical median of 1.57. Over the past decade, Cengild Medical Bhd's Debt-to-EBITDA has ranged from 0.38 to 24.31. According to the industry distribution chart, Cengild Medical Bhd ranks #340 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 71.1%.
Is Cengild Medical Bhd's Debt-to-EBITDA too high?
Cengild Medical Bhd's current Debt-to-EBITDA of 5.10 is 225% above median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 24.31. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.21. Cengild Medical Bhd's value of 5.10 is 130.8% above this industry median. Based on the distribution chart, Cengild Medical Bhd ranks #340 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cengild Medical Bhd has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cengild Medical Bhd ranks #340 out of 478 companies for Debt-to-EBITDA. This places Cengild Medical Bhd in the lower half of its industry. The industry median Debt-to-EBITDA is 2.21. Cengild Medical Bhd's value of 5.10 is 130.8% above this benchmark. Historically, Cengild Medical Bhd's own Debt-to-EBITDA has ranged from 0.38 to 24.31 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 2.21, Cengild Medical Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cengild Medical Bhd's current Debt-to-EBITDA of 5.10 is 130.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cengild Medical Bhd. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current Debt-to-EBITDA is 5.10, which is 225% above median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.19 — trading 34.5% below its estimated fair value. The current Debt-to-EBITDA is 5.10, which is 225% above median its 10-year median of 1.57 and 130.8% above the Healthcare Providers & Services industry median of 2.21. Cengild Medical Bhd's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current Debt-to-EBITDA is 5.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?
Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued.
The current stock price of RM0.19 is trading 34.5% below its estimated GF Value™ of RM0.29.
GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0243:
Debt-to-EBITDA: 5.10 (225% above median its 10-year median of 1.57)
GF Value™: RM0.29 vs. price of RM0.19 (34.5% below fair value)
Industry Position: 130.8% above the Healthcare Providers & Services median (#340 of 478)
No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
61GF Score
Get the complete analysis for XKLS:0243
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0243 has been successfully added to your 
